Literature DB >> 19072907

Stimulating personality: ethical criteria for deep brain stimulation in psychiatric patients and for enhancement purposes.

Matthis Synofzik1, Thomas E Schlaepfer.   

Abstract

Within the recent development of brain-machine-interfaces deep brain stimulation (DBS) has become one of the most promising approaches for neuromodulation. After its introduction more than 20 years ago, it has in clinical routine become a successful tool for treating neurological disorders like Parkinson's disease, essential tremor and dystonia. Recent evidence also demonstrates efficacy in improving emotional and cognitive processing in obsessive-compulsive disorder and major depression, thus allowing new treatment options for treatment refractory psychiatric diseases, and even indicating future potential to enhance functioning in healthy subjects. We demonstrate here that DBS is neither intrinsically unethical for psychiatric indications nor for enhancement purposes. To gain normative orientation, the concept of "personality" is not useful--even if a naturalistic notion is employed. As an alternative, the common and widely accepted bioethical criteria of beneficence, non-maleficence, and autonomy allow a clinically applicable, highly differentiated context- and case-sensitive approach. Based on these criteria, an ethical analysis of empirical evidence from both DBS in movement disorders and DBS in psychiatric disease reveals that wide-spread use of DBS for psychiatric indications is currently not legitimated and that the basis for enhancement purposes is even more questionable. Nevertheless, both applications might serve as ethically legitimate, promising purposes in the future.

Entities:  

Mesh:

Year:  2008        PMID: 19072907     DOI: 10.1002/biot.200800187

Source DB:  PubMed          Journal:  Biotechnol J        ISSN: 1860-6768            Impact factor:   4.677


  37 in total

1.  Informed Consent in Implantable BCI Research: Identifying Risks and Exploring Meaning.

Authors:  Eran Klein
Journal:  Sci Eng Ethics       Date:  2015-10-23       Impact factor: 3.525

2.  [Brain stimulation procedures. Transcranial magnetic stimulation, magnetic seizure therapy and deep brain stimulation].

Authors:  T E Schläpfer; S Kayser
Journal:  Nervenarzt       Date:  2012-01       Impact factor: 1.214

3.  Man, machine and in between.

Authors:  Jens Clausen
Journal:  Nature       Date:  2009-02-26       Impact factor: 49.962

Review 4.  [New indications for deep brain stimulation: ethical criteria for research and therapy].

Authors:  M Synofzik
Journal:  Nervenarzt       Date:  2013-10       Impact factor: 1.214

Review 5.  [Neuro-enhancement. Brain doping].

Authors:  H Förstl
Journal:  Nervenarzt       Date:  2009-07       Impact factor: 1.214

Review 6.  Deep brain stimulation as a new therapeutic approach in therapy-resistant mental disorders: ethical aspects of investigational treatment.

Authors:  Jens Kuhn; Wolfgang Gaebel; Joachim Klosterkoetter; Christiane Woopen
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2009-11       Impact factor: 5.270

Review 7.  [Deep brain stimulation as possible alternative for therapy resistant depression].

Authors:  T E Schläpfer
Journal:  Nervenarzt       Date:  2014-02       Impact factor: 1.214

8.  The Mind and the Machine. On the Conceptual and Moral Implications of Brain-Machine Interaction.

Authors:  Maartje Schermer
Journal:  Nanoethics       Date:  2009-12-01       Impact factor: 0.917

9.  Ethical Issues in Deep Brain Stimulation Research for Treatment-Resistant Depression: Focus on Risk and Consent.

Authors:  Laura B Dunn; Paul E Holtzheimer; Jinger G Hoop; Helen S Mayberg; Paul S Appelbaum
Journal:  AJOB Neurosci       Date:  2011

10.  Participants' Perceptions of Deep Brain Stimulation Research for Treatment-Resistant Depression: Risks, Benefits, and Therapeutic Misconception.

Authors:  Yan Leykin; Paul P Christopher; Paul E Holtzheimer; Paul S Appelbaum; Helen S Mayberg; Sarah H Lisanby; Laura B Dunn
Journal:  AJOB Prim Res       Date:  2011-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.